

# Liliana Lucia Preoțescu

## EXPERIENȚA PROFESIONALĂ

---

### Sef de lucrari

*Universitatea de Medicina si Farmacie "Carol Davila"* [ 2017 - În curs ]

Localitatea: Bucuresti

Țara: România

Descrieți sarcinile și responsabilitățile dumneavoastră.

### Medic Primar Boli Infectioase

*Institutul National de Boli Infectioase "Prof. Dr. Matei Bals"* [ 1998 - În curs ]

Localitatea: Bucuresti

Țara: România

### Investigator Principal

[ 2017 - În curs ]

Localitatea: Bucuresti

Țara: România

Cercetare clinica in conformitate cu normele de buna practica GCP  
Studii clinice de faza I, II si III - anexa atasata

## EDUCAȚIE ȘI FORMARE PROFESIONALĂ

---

### Sef de Lucrari

*Universitatea de Medicina si Farmacie "Carol Davila"* [ 2017 - În curs ]

Adresă: Bucuresti (România)

### Asistent Universitar

*Universitatea de Medicina si Farmacie "Carol Davila"* [ 1994 - 2017 ]

Adresă: Bucuresti (România)

**Doctor in Medicina cu lucrarea de doctorat: "Cercetari clinice si de laborator privind eficienta carbapenemelor, comparativ cu alte betalactamine in infectii bacteriene severe."**

*Universitatea de Medicina si Farmacie "Carol Davila"* [ 2008 ]

Adresă: Bucuresti (România)

### Medic Specialist Boli Infectioase

*Ministerul Sanatatii* [ 1991 - 1994 ]

Adresă: Bucuresti (România)

### Preparator

*Universitatea de Medicina si Farmacie "Carol Davila" - Clinica II de Boli Infectioase Colentina* [ 1989 - 1994 ]

Adresă: Bucuresti (România)

**Medic Echivalent Rezident Boli Infectioase**

*Ministerul Sanatatii- Clinica II Boli Infectioase, Colentina* [ 1989 - 1991 ]

Adresă: Bucuresti (România)

**Medic- Medicina Generala**

*Universitatea de Medicina si Farmacie "Carol Davila"* [ 1983 - 1989 ]

Adresă: Bucuresti (România)

**PUBLICAȚII**

---

**Ghid pentru gestionarea sănătății la locul de muncă**

[2015]

- a. Capitolul 8.13: Leptospiroza. Autor: Preoțescu LL.
- b. Capitolul 8.14: Hepatita virală A. Autor: Preoțescu LL.
- c. Capitolul 8.15: Înțepătura de insecte (albină, viespe, păianjen, căpușe, etc.). Autor: Preoțescu LL.
- d. Capitolul 8.16: Mușcătura de șarpe, animale sălbatice. Autor: Preoțescu LL.
- e. Capitolul 8.17: Mușcătura de animale și păsări domestice (cal, porc, vacă, oale, găscă, etc.). Autor: Preoțescu LL.
- f. Capitolul 8.18: Zoonoze. Autor: Preoțescu LL.

**Tratat de Boli Infectioase**

[2020]

Infectii ale cailor respiratorii superioare

**Boli Infectioase: Curs pentru studenti si medici rezidenti**

[2021]

Capitolul 28: Infectiile urinare

**Articole stiintifice publicate in reviste cotate ISI**

Anexa atasata

**Articole publicate în reviste indexate BDI sau CNCIS**

Anexa atasata

**PROIECTE**

---

**Model de ingrijire a pacientilor cu HTA si a complicatiilor pentru medicii practicieni.**

[ 1998 - 2003 ]

**Aplicatii ale logicii fuzzy si a teoriei probabilitatilor in medicina in diagnosticul bolilor infectioase**

[ 2002 - 2004 ]

**Impact of Pneumococcal infections in children aged 0-5 years in the Romanian HealthCare System**

[ 2013 ]

Grant Pfizer. Buget: 43597007.77RON.

Implementarea vaccinarii nationale

**Inlocuirea punctiei biopsie hepatica cu investigatii moderne paraclinice- Fibrosure.**

[ 2005 - 2007 ]

Director de program - Programul European Profesional Leonardo da Vinci

**SATURN - Impact of Specific Antibiotic Therapy on the Prevalence of Human Host Resistant Bacteria - Seventh Framework European Programme FP7**

[ 2009 – 2014 ]

Responsabil de partener INBI "Prof.Dr. Matei Bals"

Buget: 75.057.83 EUR

**DG SANCO Public Health Program**

[ 2008 – 2013 ]

Partener asociat

**HProImmune: Promovarea imunizării la Personalul Medical din Europa**

[ 2011 – 2013 ]

Manager de Proiect INBI "Prof.Dr.Matei Bals"

Buget: 62461 EUR

**DISTINȚII ONORIFICE ȘI PREMII**

---

**PRECISI 2021**

Unitatea executiva pentru Finantarea Invatamantului Superior, a Cercetării, Dezvoltării și Inovării [ 2021 ]

Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden Disease

**COMPETENȚE DE MANAGEMENT ȘI CONDUCERE**

---

**Sef Sectie- Sectia Adulti II Boli Infectioase- Institutul de Boli Infectioase "Prof. Dr. Matei Bals"**

**Presedinte Comisia de Boli Infectioase si lupta Anti- SIDA**

2015-2017

**PERMIS DE CONDUCERE**

---

Permis de conducere: B

**COMPETENȚE DIGITALE**

---

Microsoft Office / Clinical Trial Software (DataLabs, iMedidata, CleanWeb, Viedoc, Veeva Vault eTMF) / Rave iMedidata / Zoom / Microsoft PowerPoint / ePIP

**COMPETENȚE LINGVISTICE**

---

Limbă(i) maternă(e): **română**

**Altă limbă (Alte limbi):**

**engleză**

**COMPREHENSIUNE ORALĂ C1 CITIT C1 SCRIS C1**

**EXPRIMARE SCRISĂ B2 CONVERSAȚIE B2**

**franceză**

**COMPREHENSIUNE ORALĂ B1 CITIT B1 SCRIS B1**

**EXPRIMARE SCRISĂ A2 CONVERSAȚIE A2**

12 IAN 2023



## Investigator Principal – Studii Clinice

1. A phase IIIb, randomized, open label treatment, multicenter safety and efficacy of GW 33 908 (700mg BID) + Ritonavir (100mg BID) Versus Lopinavir / Ritonavir (400mg/100mg BID) administered in combination with Abacavir / Lamivudine (600 / 300mg) FDC OD in adult antiretroviral-naïve HIV-1 for 48 weeks
2. ML – 18089 Efficacy and safety of Pegasys in patients with HbeAg positive chronic hepatitis B
3. MV – 18220 – A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV toxicities in patients with current, historical treatment – limiting toxicities.
4. A Double – Blind, Randomized, Placebo – Controlled Multi – Center, Phase II Parallel Dose – Ranging Study to Assess the Antifibrotic Activity of G1262570 in Chronic Hepatitis C Subjects with Hepatic Fibrosis who have Failed Prior Antiviral Therapy.
5. A phase IV, randomised, multicentre, double blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B\*5701) for susceptibility to abacavir hypersensitivity.
6. A Multicenter, Randomized, Double – Blind, Comparative Study to evaluate the safety, tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the treatment of invasive Candidiasis in Adults.
7. A Phase IV, Randomised, Multicentre, Double-Blind Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B\*5701) for Susceptibility to Abacavir Hypersensitivity
8. Endure – A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus – The ENDURE Study.
9. FBX104114 GSK - The double blind, randomized, placebo-controlled, multicenter study with parallel dose regimens to assess the antifibrotic activity of G1262570 in chronic Hepatitis C virus from patients with liver fibrosis who had a previous failure of antiviral therapy
10. HPR20001 GSK Phase IIb, randomized, multicenter, parallel group evaluating short-term safety, pharmacokinetics, and antiviral activity of four blind therapy regimens compared GW640385/Ritonavir protease inhibitor therapy in patients with HIV-1 infected PI experienced adults for 2 weeks to assess long-term (> 48 weeks) the safety, pharmacokinetics and antiviral activity of selected regimens Ritonavir-boosted vs GW640385/Ritonavir, PI-containing regimens.
11. GSK-. Study the prevalence of lipodystrophy evaluation Lipo in a large group of patients, children and adults with HIV infection
12. MSD-801-00-study multicenter, randomized, double-blind, comparative, in order to evaluate the safety, tolerability and efficacy of two dose regimens during treatment with caspofungin in invasive candidiasis in adults.
13. KareAP - PMOS-EAST-04-02 Abbott-clinical results, biological and virological, compliance and tolerance transition to a system containing Kaletra® in patients moderately advanced in clinical practice a postmarketing observational study noninterventive, multicenter, multinational



14. KaleEAST - PMOS-EAST-04-01-Abbott-study post-marketing observational, multicenter study conducted in several countries, the consequences, compliance and tolerability clinical, biological and virological the Kaletra  $\square$  in routine clinical use

15. Nr.1100.1470 Artene-Boehringer Ingelheim, simple clinical trial, randomized to compare the efficacy and safety of viral Atazanavir / Ritonavir Associated with Tenofovir and Emtricitabine background medication vs. medication Nevirapine in combination with the same background, HIV-1 patients not had previously received antiretroviral treatment. (Phase III b)

16. AI463-080-Abcro-Randomized,Observational Study of Entecavir to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection:The REALM Study (phaseIV)

17. ICLA-20-PNE1-PSI-Randomized,double-blind,multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired,ventilator-associated,or health-care-associated pneumonia suspected or confirmed to be due to Gram-positive pathogenens..

18. MV No. 21012 - 1-Roche-Propheys observational prospective study of predictors of response factors of early and sustained viral response in a cohort of naive patients infected with HCV treated with pegylated interferon.

19. Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 24 weeks as combination therapy with pegylated interferon- $\alpha$  2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).

20. Randomised, placebo-controlled,multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus(HCV) infection who are otherwise eligible to initiate antiviral therapy(peginterferon alfa 2b plus ribavirin)(ENABLE 2)

21.Randomised, placebo-controlled,multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus(HCV) infection who are otherwise eligible to initiate antiviral therapy(peginterferon alfa 2a plus ribavirin)(ENABLE 1)

22. Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 24 weeks as combination therapy with pegylated interferon- $\alpha$  2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).

23. BI 1220.40 -Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-  $\alpha$  2a and ribavirin (open label, randomized, Phase II)

24. BI 1241.21-Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with ribavirin for 4 (part 1) and with or without ribavirin for 24-48 weeks(part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, phase II)

25. A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral Therapy-Experienced Adults.



26. A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection
27. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
28. Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination with Standard-of-Care Neuraminidase Inhibitor in Hospitalized Patients with Severe Influenza
29. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis.
30. SMT19969/C005 A Phase 3, Randomized, Double-Blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, *\_bid*) for 10 Days with Vancomycin (125 mg, *qid*) for 10 Days in the Treatment of Clostridium Difficile
31. A Phase 3, Multicenter, Randomized, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalization for Management of Moderate COVID 19.

### Articole stiintifice in reviste cotate ISI

- 1.Haeuser E, Serfes AL, Cork MA, ..., Preotescu L, ..., Dwyer-Lindgren L; Local Burden of Disease sub-Saharan Africa HIV Prevalence Collaborators. Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018. BMC Med. 2022 Dec 19;20(1):488. doi: 10.1186/s12916-022-02639-z. ISSN 1741-7015. IF(2021): 11.806
- 2.Săndulescu O, Streinu-Cercel A, Moțoi MM, Streinu-Cercel A, Preoțescu LL. Syndromic Testing in Infectious Diseases: From Diagnostic Stewardship to Antimicrobial Stewardship. Antibiotics (Basel). 2023;12(1):6. doi: 10.3390/antibiotics12010006. ISSN 2079-6382. IF(2021): 5.222
- 3.Sandulescu O, Viziteu I, Streinu-Cercel A, Miron VD, Preoțescu LL, Chirca N, Albu SE, Craiu M, Streinu-Cercel A. Novel antimicrobials, drug delivery systems and antivirulence targets in the pipeline—from bench to bedside. Appl Sci. 2022;12:11615. (contributii egale) doi: 10.3390/app122211615. ISSN/eISSN: 2076-3417. IF(2021): 2.838.
- 4.Kim JY#, Săndulescu O#, Preotescu LL#, Rivera-Martínez NE, Dobryanska M, Birlutiu V, Miftode EG, Gaibu N, Caliman-Sturdza O, Florescu SA, Shi HJ, Streinu-Cercel A, Streinu-Cercel A, Lee SJ, Kim SH, Chang I, Bae YJ, Suh JH, Chung DR, Kim SJ, Kim MR, Lee SG, Park G, Eom JS. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. Open Forum Infect Dis. 2022 Aug 8;9(8):ofac406. doi: 10.1093/ofid/ofac406. (#Contribuții egale). Online ISSN 2328-8957. IF (2021): 4.433.
- 5.Streinu-Cercel A#, Săndulescu O#, Preotescu LL#, Kim JY, Kim YS, Cheon S, Jang YR, Lee SJ, Kim SH, Chang I, Suh JH, Lee SG, Kim MR, Chung DR, Kim HN, Streinu-Cercel A, Eom JS. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. Open Forum Infect Dis. 2022 Feb



2;9(4):ofac053. doi: 10.1093/ofid/ofac053. Online ISSN 2328-8957. Factor de impact (2021): 4.433. #Co-prim autor.

6.Săndulescu O, Irimia M, Benea OE, Mărdărescu M, Preotescu LL, Dorobăț CM, Loghin II, Nicolau IC, Jipa RE, Popescu RȘ, Benea CL, Cozma A, Dărămuș IA, Miron VD, Prisăcariu LJ, Bahnă AF, Nistor I, Secrieru OM, George S, Bîrcă A, Dobrea L, Șogorescu AȘ, Viziteu I, Streinu-Cercel A. Treatment initiation or switch to BIC/FTC/TAF - real-world safety and efficacy data from two HIV centers in Romania. *Germs*. 2021 Dec 29;11(4):512-522. doi: 10.18683/germs.2021.1286. ISSN: 2248-2997. Web of Science Core Collection.

7.Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, ..., Preotescu L, ..., Force LM. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. *JAMA Oncol*. 2022 Mar 1;8(3):420-444. doi: 10.1001/jamaoncol.2021.6987. IF(2021):33.012.

8.Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S; ARREST investigator study group (Preotescu L et al), Sanyal AJ. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. *Nat Med*. 2021 Oct;27(10):1825-1835. doi: 10.1038/s41591-021-01495-3. IF 2021: 87.241

9.GBD 2019 Viewpoint Collaborators (Abbasfati C, ..., Preotescu L, et al.). Five insights from the Global Burden of Disease Study 2019. *Lancet*. 2020 Oct 17;396(10258):1135-1159. doi: 10.1016/S0140-6736(20)31404-5. PMID: 33069324; PMCID: PMC7116361. IF (2020): 79.323

10.GBD 2019 Demographics Collaborators (Wang H, ..., Preotescu L, et al.). Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020 Oct 17;396(10258):1160-1203. doi: 10.1016/S0140-6736(20)30977-6. PMID: 33069325; PMCID: PMC7566045. IF (2020): 79.323

11.GBD 2019 Diseases and Injuries Collaborators (Abbasfati C, ..., Preotescu L, et al.). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. PMID: 33069326; PMCID: PMC7567026. IF (2020): 79.323

12.Local Burden of Disease WaSH Collaborators (Deshpande A, ..., Preotescu L, et al.). Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17. *Lancet Glob Health*. 2020 Sep;8(9):e1162-e1185. doi: 10.1016/S2214-109X(20)30278-3. PMID: 32827479; PMCID: PMC7443708. IF (2020): 26.763.

13.Local Burden of Disease Diarrhoea Collaborators (Wiens KE, ..., Preotescu L, et al.). Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17. *Lancet Glob Health*. 2020 Aug;8(8):e1038-e1060. doi: 10.1016/S2214-109X(20)30230-8. PMID: 32710861; PMCID: PMC7388204. IF (2020): 26.763.

14.LBD Double Burden of Malnutrition Collaborators (Kinyoki DK, ... Preotescu L, et al.). Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. *Nat Med*. 2020 Aug;26(8):1308. doi: 10.1038/s41591-020-0972-7. Erratum for: *Nat Med*. 2020 May;26(5):750-759. PMID: 32616917; PMCID: PMC7417329. IF (2020): 53.440.



15. Local Burden of Disease Diarrhoea Collaborators (Reiner RC Jr, ..., Preotescu L, et al.). Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020 Jun 6;395(10239):1779-1801. doi: 10.1016/S0140-6736(20)30114-8. Epub 2020 May 6. PMID: 32513411; PMCID: PMC7314599. IF (2020): 79.323
16. Niehus R, van Kleef E, Mo Y, Turlej-Rogacka A, Lammens C, Carmeli Y, Goossens H, Tacconelli E, Carevic B, Preotescu L, Malhotra-Kumar S, Cooper BS. Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. *Elife*. 2020 May 7;9:e49206. doi: 10.7554/eLife.49206. PMID: 32379042; PMCID: PMC7205461. IF (2020): 8.146
17. LBD Double Burden of Malnutrition Collaborators (Kinyoki DK, ..., Preotescu L, et al.). Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. *Nat Med*. 2020 May;26(5):750-759. doi: 10.1038/s41591-020-0807-6. Epub 2020 Apr 20. PMID: 32313249; PMCID: PMC7220891. IF (2020): 53.440.
18. Boccara F, Kumar PN, Caramelli B, Calmy A, López JAG, Bray S, Cyrille M, Rosenson RS; BEIJERINCK Investigators (Baker D, ..., Preotescu LL, et al.). Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. *J Am Coll Cardiol*. 2020 May 26;75(20):2570-2584. doi: 10.1016/j.jacc.2020.03.025. Epub 2020 Mar 28. PMID: 32234462. IF (2020): 24.093.
19. Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHT Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. *N Engl J Med*. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. PMID: 32212519. IF (2020): 91.253.
20. Tacconelli E, Górska A, De Angelis G, Lammens C, Restuccia G, Schrenzel J, Huson DH, Carević B, Preotescu L, Carmeli Y, Kazma M, Spanu T, Carrara E, Malhotra-Kumar S, Gladstone BP. Estimating the association between antibiotic exposure and colonization with extended-spectrum  $\beta$ -lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study. *Clin Microbiol Infect*. 2020 Jan;26(1):87-94. doi: 10.1016/j.cmi.2019.05.013. PMID: 31128285. IF (2020): 8.067.
21. Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH. Cadazolid for the treatment of *Clostridium difficile* infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. *Lancet Infect Dis*. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29. PMID: 30709665. IF (2019): 24.446
22. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, About M, Smith K; GEMINI Study Team (Cassetti L, David D, Figueras L, Figueroa Losso M, Lopardo G, Lupo S, Porteiro N, Sánchez M, Bloch M, Cooper D, Finlayson R, Koh K, Lewis D, McMahon J, Moore R, Roth N, De Wit S, Florence E, Goffard JC, Demeester R, Lacor P, Vandercam B, Vandekerckhove L, Angel J, Baril JG, Conway B, De Pokomandy A, Szabo J, Walmsley S, Bouchaud O, Chidiac C, Delobel P, Goujard C, Katlama C, Molina JM, Pialoux G, Philibert P, Bogner J, Esser S, Krznaric I, Lehmann C, Spinner C, Stellbrink HJ, Stephan C, Stoehr A, Barchi E, Caramello P, Castelli F, Cattelan AM, D'Arminio Monforte A, Di Biagio A, Di Perri G, Gori A, Maggiolo F, Mussini C, Penco G, Puoti M, Rizzardini G, Gulminetti R, Lazzarin A, Quirino T, Sighinolfi L, Viale P, Amaya Tapia G, Andrade Villanueva J, Granados Reyes ER, Perez Rios A, Santosco Y Gomez M, Den Hollander J, Rijnders B,



Hidalgo JA, Hercilla L, Illescas L, Olczak A, Mansinho K, Correia Pacheco PP, Teófilo E, Saraiva da Cunha J, Sarmiento E Castro R, Serrão R, Arbune M, Jianu C, Preotescu L, Prisacariu LJ, Belonosova E, Borodkina O, Chernova O, Gankina N, Kizhlo S, Kulagin V, Kurina N, Nagimova F, Pokrovsky V, Riamova E, Voronin E, Yakovlev A, Kaplan R, Lee SH, Kim SW, Kim SI, Kim WJ, Antela Lopez A, Casado Osorio JL, Castaño Carracedo MA, De Los Santos Gil I, Estrada Perez V, Falco V, Force L, Galinda Puerto MJ, Garcia Deltoro M, Gatell JM, Goenaga Sanchez MA, Knobel H, Lopez Bernaldo de Quiros JC, Losa Garcia JE, Masia M, Montero-Alonso M, Ocampo Hermida A, Pasquau J, Portilla Sogorb J, Pulido F, Rivera Roman A, Santos Fernandez JR, Torres Perea R, Troya J, Viciano P, Calmy A, Hauser C, Fehr J, Cheng SH, Ko WC, Lin HH, Lu PL, Tseng YT, Wang NC, Wong WW, Yang CJ, Arduino R, Benson P, Berhe M, Bredeek F, Benson P, Brinson C, Campbell T, Crofoot G, Cunningham D, DeJesus E, Dretler R, Eron J, Fife K, Fichtenbaum C, Flamm J, Goldstein D, Hagins D, Hoffman-Terry M, Jayaweera D, Kinder C, Klein D, McDonald C, Mills A, Nahass R, Osiyemi O, Overton E, Parks D, Prelutsky D, Ramgopal M, Schrader S, Sims J, Skiest D, Slim J, Tashima K, Thedinger B, Gazzard B, Fox J, Johnson M, Kegg S, Khoo S, Mazhude C, Orkin C, Schembri G, Ustianowski A.). Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet*. 2018 Nov 9. pii: S0140-6736(18)32462-0. doi: 10.1016/S0140-6736(18)32462-0. IF (2018): 59.102

23. Meletiadiş J, Turlej-Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW; the SATURN Diagnostic Study Group (Malhotra-Kumar S, Goossens H, Lammens C, Percia S, De Angelis G, Restuccia G, Preotescu L, Popoiu M, Carevic B, Tosic T, Harbarth S, Carmeli Y.). Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone. *Antimicrob Agents Chemother*. 2017 Oct 24;61(11). pii: e00473-17. doi: 10.1128/AAC.00473-17. IF 2017: 4.256.

24. Nişescu M, Vâjâltu C, Săndulescu O, Streinu-Cercel A, Pişigoi D, Preoşescu LL, Streinu-Cercel A. Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. *Rom J Lab Med*. 2017;25(4):355-363. doi: 10.1515/rrlm-2017-0030. Clarivate Analytics (Thomson Reuters) Journal Citation Report – ISI – impact factor (2017) 0.400. ISSN: 1841-6624. Contributii egale

25. Streinu-Cercel A, Săndulescu O, Manolache D, Stoica MA, Preoşescu LL, Streinu-Cercel A. Drug-drug interaction (DDI) tools – useful versus mandatory in the management of difficult to treat patients with chronic HCV infection. *Farmacia*. 2017;65(1):136-141. Thomson Reuters Journal Citation Report – ISI – impact factor (2017) 1.507. ISSN: 0014-8237.

26. Streinu-Cercel A, Sandulescu O, Ceapraga G, Manolache D, Stoica MA, Preotescu LL, Streinu-Cercel A. Prevalence of osteo-renal impairment in the Romanian HIV cohort. *BMC Infect Dis* 2016, 16(Suppl 1):93, p 11-16 doi: 10.1186/s12879-016-1397-2 IF 2016: 2.768. ISSN 1471-2334 RIS 2015: 1.614 Galben UEFISCDI #25 2016

27. Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group (Basho J, Shabanaj G, Harxhi A, [...], Preotescu L, et al.) Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. *PLoS One*. 2016;11(3):e0151703. doi: 10.1371/journal.pone.0151703. IF(2016): 2.806. ISSN 1932-6203 Rosu UEFISCDI #13 2016

28. Ratzu V, Harrison S, Francque S, Bedossa P, Leheret P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee Q, Hum D, Hanf R, Roudot A, Megnier S, Staels B, Sanyal



A; GOLDEN-505 Investigator Study Group. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- $\alpha$  and - $\delta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. *Gastroenterology*. 2016 Feb 11. pii: S0016-5085(16)00140-2. doi: 10.1053/j.gastro.2016.01.038. FI(2016): 18.392, ISSN 0016-5085 RIS 2015: 6.916 Rosu UEFISCDI #1 2016

29.Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, Morillas RM, Hall C, Mobashery N, Redman R, Pilot-Matias T, Vilchez RA, Hézode C. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. *Gastroenterology*. 2015 Oct;149(4):971-80.e1. doi: 10.1053/j.gastro.2015.07.001. Epub 2015 Jul 11. FI(2015): 18.187, ISSN 0016-5085 RIS 2015: 6.916 Rosu UEFISCDI #1 2016

30.Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C; FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. *Lancet HIV*. 2015 Apr;2(4):e127-36. doi: 10.1016/S2352-3018(15)00027-2. Epub 2015 Mar 10. FI(2015): 8.364 ISSN 2352-3018 Rosu UEFISCDI #2 2016

31.Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet*. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1. IF(2014): 45.217 ISSN: 0140-6736 RIS 2015: 48.197 Rosu UEFISCDI #2 2016

32.Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GJ, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. *Clin Gastroenterol Hepatol*. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12. IF(2014): 7.896. ISSN 1542-3565 RIS 2015 3.604 Rosu UEFISCDI #7 2016

33.Gheorghe L, Iacob S, Simionov I, Caruntu F, Motoc A, Arama V, Preotescu L, Stefan I, Goldis A, Brisc C, Rugina S, Rednic N. A Real Life Boceprevir Use in Treatment-Experienced HCV Genotype Patients with Advanced Fibrosis. *J Gastrointest Liver Dis*. 2014 Mar;23(1):45-50. IF(2014): 2.202, ISSN 1841-8724 RIS 2015: 0.770

34.Fronie A, Bunget A, Afrem E, Preotescu LL, Corlan Pușcu D, Streba L, Mogoantă L, Dumitrescu D. Squamous cell carcinoma of the oral cavity: clinical and pathological aspects. *Rom J Morphol Embryol*. 2013;54(2):343-8. IF(2013): 0.723, ISSN 1220-0522 RIS 2015: 0.144 (contributii egale)

### Articole publicate în reviste indexate BDI sau CNCSIS

1.Streinu-Cercel A, Săndulescu O, Preotescu LL, Streinu-Cercel A. Prevalence of bone demineralization in HIV-positive patients. *J Contemp Clin Pract*. 2016;2(1):25-30. doi: 10.18683/jccp.2016.1009. ISSN 2457-7200

2.Săndulescu O, Streinu-Cercel A, Săndulescu M, Neagu AC, Calistru PI, Berciu I, Preotescu LL, Streinu-Cercel A. Quorum sensing and biofilm formation in *Staphylococcus* species. *Ther Pharmacol Clin Toxicol*. 2015;19(2):45-51. CNCSIS B+, ISSN 2066-0170



3. Preda M, Gheorghe AS, Preoțescu L. Hepatitis in our times – problems and therapeutic solutions. *Infectio.ro* 2015;42(2):29-34. ISSN 1841-348X
4. Iordache EL, Aron G, Preoțescu L, Coliță A, Georgescu D. Reactivation of chronic hepatitis with B virus in non-Hodgkin lymphoma with small B-cell associated with chronic kidney disease. *Rom J Infect Dis.* 2015;18(1):30-33. ISSN 1454-0398
5. Preoțescu L, Noddea ME, Popa MI. Prior antibiotic use, a risk factor for infection with multidrug resistant bacteria. *Infectio.ro* 2014;39(3):13-15. ISSN 1841-348X
6. Iordache EL, Aron G, Preoțescu L, Georgescu D, Sinescu CJ. Reactivarea hepatitei cronice cu VHB în limfomul nonHodkin cu celulă mică B. *Medicina internă* 2014;11(4):115-120. ISSN 1220-5818
7. Iordache EL, Aron G, Cecil O, Oprea R, Preoțescu L, Georgescu D. Clinical study on monitoring criteria of entecavir treatment in chronic hepatitis with B virus. *Rom J Infect Dis.* 2013;16(3):172-177. ISSN 1454-0398
8. Iordache EL, Aron G, Cecil O, Oprea R, Preoțescu L, Georgescu D. Clinical study on the role of entecavir in chronic hepatitis with B virus. *Rom J Infect Dis.* 2013;16(2):90-95. ISSN 1454-0398
9. Preoțescu LL, Streinu-Cercel O. Prevalence of nasal carriage of *S aureus* in children. *GERMS.* 2013;3(2):49-51. doi: 10.11599/germs.2013.1035. ISSN 2248-2997
10. Streinu-Cercel O, Streinu-Cercel A, Preoțescu LL, Streinu-Cercel A. Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. *GERMS.* 2012;2(1):18-22. doi: 10.11599/germs.2012.1009. ISSN 2248-2997
11. Calin R, Preoțescu L, Streinu-Cercel A, Streinu-Cercel A. Impactul sindromului metabolic asupra bolii de ficat, la pacienții coinfectați HIV-VHB/VHC. *Medicina Internă.* 2012. ISSN 1220-5818
12. Streinu-Cercel A, Rebedea I, Streinu-Cercel O, Streinu-Cercel A, Preoțescu L, Manolache D. Hepatitis C virus superinfection in individuals with chronic hepatitis B virus infection. A comparative case study. *Ther Pharmacol Clin Toxicol.* 2010;14(1):25-35. CNCSIS B+, ISSN 2066-0170.
13. Streinu-Cercel A, Preoțescu L, Streinu-Cercel A, Călin A, Budulac A, Streinu-Cercel O. Correlations between non-invasive explorations and liver biopsy in the determination of liver fibrosis in chronic viral hepatitis C. *Ther Pharmacol Clin Toxicol,* 2009;13(3):281-286, CNCSIS B+, ISSN 2066-0170.
14. Preoțescu L, Popa GL, Motol M, Streinu-Cercel A, Popa MI. *Aspergillus fumigatus* meningitis in immunosuppressed patients; diagnosis, management, prevention and control. *Roum Arch Microbiol Immunol.* 2009;68(2):95-9.